Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis of human stage Ta and stage T1 bladder tumours

ABSTRACT: Expression analysis of human stage Ta and stage T1 bladder tumours

PROVIDER: PRJNA685205 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression analysis of human stage Ta and stage T1 bladder tumours

Project description:Expression data derived from this analysis was used for transcriptional subtyping and to compare expression features of genomic subgroups In this dataset, we include the expression data obtained from 113 stage Ta and 104 stage T1 bladder tumours

2021-02-22 | GSE163209 | GEO

Expression analysis of human stage Ta bladder tumours

Project description:Expression data derived from this analysis was used to compare expression signatures between genomic subgroups identified from DNA copy number analysis. In this dataset, we include the expression data obtained from 79 stage Ta primary bladder tumours

2018-06-15 | GSE93527 | GEO

Whole-exome sequencing of paired tumour/blood of 58 T1 stage bladder cancer patients

Project description:To understand the molecular determinants that underpin the clinical heterogeneity of non-muscle-invasive bladder cancer (NMIBC) we carried out whole-exome sequencing (WES) of stage T1 bladder tumours to identify prognostic biomarkers and novel therapeutic targets. The study includes paired tumour/blood samples of 58 T1 stage bladder cancer patients.

| EGAS00001005765 | EGA

Transcription profiling of human bladder tumours to construct a tumour stage classifier

Project description:Bladder tumours used to construct a tumour stage classifier

2007-09-28 | E-GEOD-89 | biostudies-arrayexpress

Identification of Differential Tumor Subtypes of T1 Bladder Cancer

Project description:Stage T1 bladder cancers have the highest progression and recurrence rates of all non-muscle invasive bladder tumors. T1 tumors are heterogeneous; while most T1 patients are treated with BCG, many will progress and die from bladder cancer, and particularly aggressive tumors could be treated by early cystectomy. To better understand the molecular heterogeneity of T1 cancers, we performed transcriptome profiling and unsupervised clustering, identifying five consensus subtypes of T1 tumors treated with reTUR, induction and maintenance BCG. The T1-LumGU subtype was associated with CIS (6/13, 46% of all CIS), had high E2F1 and EZH2 expression, and enriched E2F target and G2M checkpoint Hallmarks. T1-Inflam was inflamed and infiltrated with immune cells. While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median Luminal Papillary score and FGFR3 expression, no recurrence events, and the fewest copy number gains. T1-Myc and T1-Early subtypes had the most recurrences (14/30 within 24 months), highest median MYC expression, and, when combined, had significantly worse recurrence-free survival than the other three subtypes. T1-Early had 5 (38%) recurrences within the first 6 months of BCG, and repressed IFN-alpha and IFN-gamma Hallmarks and inflammation. We developed a single-patient T1 classifier and validated our subtype biology in a second cohort of T1 tumors. Future research will be necessary to validate the proposed T1 subtypes and to determine if therapies can be individualized for each subtype.

2020-07-13 | GSE154261 | GEO

Bladder tumour stage classification

Project description:Bladder tumours used to construct a tumour stage classifier Keywords = bladder cancer, disease stages, classification Keywords: other

2002-12-08 | GSE89 | GEO

Bladder Tumours O-Glycoproteomics

Project description:Bladder carcinogenesis and tumour progression is accompanied by profound alterations in protein glycosylation. These include the presence of short chain O-glycans such as Tn and T antigens and their sialylated counterparts sialyl-Tn(STn) and sialyl-T(ST). The presence of such structures is commonly associated with poor prognosis. In search for prognosis biomarkers and novel therapeutic targets we have screened, using immunohistochemistry, a series of bladder tumours with differing clinicopathology for these short-chain O-glycans. Aiming at identifying protein targets, we have studied the O-glycoproteome of a pool of STn positive tumours from muscle invasive bladder cancer (MIBC) patients.

2017-08-17 | PXD006813 | Pride

Targeted sequencing of paired tumour/blood of 34 T1 stage bladder cancer patients

Project description:Stage T1 bladder cancer presents a high risk of progression and requires improved understanding. In continuation of our whole-exome sequencing study on this subtype of the disease, we carried out this targeted paired tumour/blood sequencing study including 34 T1 stage bladder cancer patients. AgilentÃ¢Â€Â™s SureDesign tool was used to design a 1.133 Mb SureSelect custom capture for all coding exons of the 140 selected candidate genes.

| EGAS00001005767 | EGA

Targeted sequencing of paired tumour/blood of 78 Ta stage bladder cancer patients

Project description:In continuation of our whole-exome and targeted sequencing study on non-muscle-invasive bladder cancer, we carried out this targeted paired tumour/blood sequencing study including 78 Ta stage bladder cancer patients. AgilentÃ¢Â€Â™s SureDesign tool was used to design a 1.133 Mb SureSelect custom capture for all coding exons of the 140 selected candidate genes.

| EGAS00001005766 | EGA

Homo sapiens

Project description:Expression analysis of human stage Ta bladder tumours

| PRJNA360998 | ENA